Major financial data for the past five years is posted.
(￥ million)
|
Jun. 2020 |
Jun. 2021 |
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
|
|
Sales |
56,546 |
61,507 |
77,748 |
90,101 |
107,547 |
|
Operating income excluding goodwill amortization |
12,595 |
12,944 |
16,893 |
19,934 |
24,168 |
|
Operating income margin excluding goodwill amortization (%) |
22.3 |
21.0 |
21.7 |
22.1 |
22.5 |
|
EBITDA |
16,794 |
17,764 |
22,712 |
26,742 |
31,856 |
|
Operating income |
12,445 |
12,795 |
15,239 |
18,030 |
22,135 |
|
Operating income margin (%) |
22.0 |
20.8 |
19.6 |
20.0 |
20.6 |
|
Ordinary income |
12,310 |
13,196 |
16,326 |
17,635 |
21,968 |
|
Net income |
9,178 |
9,984 |
10,857 |
13,106 |
15,808 |
|
Net assets |
71,975 |
92,938 |
121,130 |
134,300 |
151,961 |
|
Total assets |
93,729 |
115,427 |
155,127 |
172,644 |
191,614 |
|
Operating cash flow |
11,166 |
8,920 |
17,302 |
19,138 |
34,708 |
|
Investment cash flow |
-10,389 |
-16,327 |
-18,703 |
-15,135 |
-21,222 |
|
Free cash flow |
777 |
-7,407 |
-1,401 |
4,003 |
13,486 |
|
Financial cash flow |
-850 |
10,110 |
11,368 |
-2,342 |
-13,878 |
|
Depreciation (including goodwill amortization) |
4,198 |
4,819 |
6,439 |
7,513 |
8,464 |
|
R＆D expenses |
6,579 |
7,524 |
8,869 |
9,723 |
11,662 |
|
Employees: Consolidated (persons) |
8,761 |
9,409 |
10,435 |
10,187 |
9,371 |
|
Employees: Non-consolidated (persons) |
875 |
925 |
1,041 |
1,016 |
1,088 |
|
Number of shares issued and outstanding (shares) |
260,561,600 |
265,972,800 |
271,633,600 |
271,633,600 |
271,633,600 |
|
Net income per share (￥) (after adjustment) |
35.25 |
38.25 |
40.01 |
48.25 |
58.20 |
|
Net assets per share (￥) (after adjustment) |
276.13 |
349.18 |
439.80 |
487.12 |
556.71 |
|
ROE (Return On Equity) (%) |
13.4 |
12.1 |
10.2 |
10.4 |
11.2 |
|
ROIC (Return On Invested Capital) (%) |
13.5 |
11.7 |
10.9 |
10.7 |
12.1 |
|
Dividend (￥) (after adjustment) |
8.81 |
11.26 |
11.99 |
14.48 |
20.37 |
|
Consolidated dividend payout ratio (%) |
25.0 |
30.0 |
30.0 |
30.0 |
35.0 |
(￥ million)
|
Jun. 2020 |
Jun. 2021 |
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
|
|
Sales |
56,546 |
61,507 |
77,748 |
90,101 |
107,547 |
|
Medical business |
47,855 |
53,068 |
68,345 |
78,552 |
95,654 |
|
Device business |
8,690 |
8,438 |
9,403 |
11,549 |
11,892 |
(￥ million)
|
Jun. 2020 |
Jun. 2021 |
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
|
|
Operating cash flow |
11,166 |
8,920 |
17,302 |
19,138 |
34,708 |
|
Investment cash flow |
-10,389 |
-16,327 |
-18,703 |
-15,135 |
-21,222 |
|
Free cash flow |
777 |
-7,407 |
-1,401 |
4,003 |
13,486 |
|
Financial cash flow |
-850 |
10,110 |
11,369 |
-2,342 |
-13,878 |
(￥ million)
|
|
Jun. 2020 |
Jun. 2021 |
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
|
Depreciation |
4,198 |
4,819 |
6,439 |
7,513 |
8,464 |
|
R＆D Expenses |
6,579 |
7,524 |
8,869 |
9,723 |
11,662 |
（％）
|
Jun. 2020 |
Jun. 2021 |
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
|
|
ROE (Return On Equity) |
13.4 |
12.1 |
10.2 |
10.4 |
11.2 |
|
ROIC (Return On Invested Capital) |
13.5 |
11.7 |
10.9 |
10.7 |
12.1 |
